You get malaria in Africa almost exclusively through the bite of an infected female Anopheles mosquito. The mosquito injects microscopic parasites into your bloodstream while feeding, and those parasites travel to your liver before multiplying and invading red blood cells. Africa carries the heaviest malaria burden on the planet, largely because the continent hosts the world’s most efficient mosquito species for spreading the disease and the most dangerous species of malaria parasite.
The Mosquitoes That Carry Malaria
Three mosquito species do most of the work spreading malaria across tropical Africa: Anopheles gambiae, Anopheles coluzzii, and Anopheles funestus. These are among the most effective malaria vectors anywhere in the world, and they’re widespread across the continent. A fourth species, Anopheles pharoensis, also transmits the disease but behaves differently, feeding primarily around dusk rather than deep into the night.
The main three species peak their biting activity between midnight and 3 a.m., which is why sleeping under a bed net matters so much. But the picture isn’t as simple as “nighttime only.” Research in the Central African Republic found that 20 to 30% of indoor biting happened during daylight hours. That means nets and indoor spraying, while critical, don’t catch every bite.
A newer threat is an invasive species called Anopheles stephensi, first detected in Djibouti in 2012 and now found as far west as Ghana. Unlike Africa’s native malaria mosquitoes, this species breeds in artificial water containers like barrels and storage tanks, allowing it to thrive in cities. Its spread could put an estimated 126 million additional people at risk by driving malaria transmission into urban areas that were traditionally low-risk.
What Happens After a Bite
When an infected mosquito bites you, it deposits tiny parasites called sporozoites into your skin along with its saliva. These parasites quickly travel through your bloodstream to your liver, where they invade liver cells and begin multiplying. After a period of silent reproduction, thousands of new parasites burst out of the liver and enter your red blood cells, where they continue multiplying. It’s this stage, the destruction of red blood cells, that causes the fever, chills, and sweating associated with malaria.
About 98.3% of malaria cases in Africa are caused by Plasmodium falciparum, the most dangerous of the five parasite species that infect humans. This species is responsible for the vast majority of severe cases and deaths. The remaining cases come mostly from Plasmodium vivax, which accounts for roughly 1.7% of infections in the region.
How Long Before You Feel Sick
Symptoms typically appear 7 to 30 days after the infective bite. Falciparum malaria tends to show up on the shorter end of that range, sometimes within a week. If you’re taking antimalarial prophylaxis while traveling, the drugs can delay symptom onset by weeks or even months, meaning you might not feel ill until well after you’ve returned home. This is especially true with certain less common parasite species that can lie dormant in liver cells and reactivate long after the original bite.
The classic symptoms are cyclical fevers, chills, headache, muscle aches, and fatigue. With falciparum malaria specifically, the illness can progress rapidly to severe disease involving organ failure, severe anemia, or cerebral malaria if untreated.
Non-Mosquito Transmission
Mosquito bites account for the overwhelming majority of cases, but malaria can also pass from mother to baby during pregnancy or childbirth. The prevalence of congenital malaria in sub-Saharan Africa varies enormously by location, ranging from less than 0.5% of newborn hospital admissions in parts of Kenya to over 20% in some areas of Uganda and Zambia. Studies in Nigeria have found rates between 5% and 17% depending on the region and the population studied. Malaria can also spread through blood transfusions and shared needles, though these routes are far less common.
Where and When Risk Is Highest
Malaria transmission depends heavily on temperature and rainfall. The parasite develops inside the mosquito most efficiently when temperatures sit between 25°C and 27°C (roughly 77°F to 81°F). Below 18°C (64°F), transmission drops off sharply, and above 32°C (90°F) it also declines. But in tropical settings, rainfall patterns often matter more than temperature because mosquitoes need standing water to breed. The weeks following rainy seasons are typically peak transmission periods.
Rural areas near stagnant water sources have traditionally carried the highest risk. Farming communities, villages near swamps or rice paddies, and areas with poor drainage are prime mosquito breeding grounds. Cities have historically been lower risk because of less standing water, better housing, and more access to healthcare. That dynamic is shifting, though, as the invasive Anopheles stephensi mosquito establishes itself in urban environments across the Horn of Africa and West Africa.
Protection That Works
Insecticide-treated bed nets remain the single most effective personal protection tool. Sleeping under one every night blocks the majority of bites since the primary vector species feed most aggressively after midnight. Indoor residual spraying, where insecticide is applied to interior walls, kills mosquitoes that land and rest indoors. Wearing long sleeves and using insect repellent during evening and nighttime hours adds another layer of protection, especially outdoors.
For travelers, antimalarial prophylaxis is highly effective when taken as prescribed. The specific drug depends on the region you’re visiting and local resistance patterns. This matters because drug-resistant strains of falciparum malaria are a growing concern. Artemisinin resistance, first documented in Southeast Asia, has now been confirmed in East Africa, and genetic markers associated with resistance have been trending upward across the continent since 2012.
Vaccines are now part of the prevention toolkit for the first time. The WHO recommended the RTS,S vaccine in 2021 and a second vaccine, R21/Matrix-M, in 2023. When given just before the high-transmission season, the R21 vaccine reduced symptomatic malaria cases by 75% over 12 months in clinical trials. In year-round dosing schedules, efficacy was 66%. A fourth booster dose given a year after the initial three-dose series maintained protection. At least 28 African countries plan to include a malaria vaccine in their national immunization programs, with rollout supported by Gavi, the Vaccine Alliance, in 18 countries. These vaccines are designed primarily for young children, who bear the greatest burden of severe disease and death.